IRVINE, Calif., May 23, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq:SNCR). Investors who purchased or otherwise acquired shares between December 6, 2016 and April 26, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the June 30, 2017 lead plaintiff motion deadline.
If you purchased Synchronoss shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, Synchronoss made false and/or misleading statements and/or failed to disclose: that the Company would not be able to meet the revenue guidance provided to investors; that Synchronoss would need to revise its prior guidance; and that as a result of the above, the Company’s statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Following this news, Synchronoss’ share price decreased materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



